Clinical Trial

JAK Inhibitor Dose TAPering Strategy Study

Study acronym: JAK-TAP
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study aims to assess the feasibility of tapering JAK inhibitors in rheumatoid arthritis patients in low disease activity by comparing a group of patients tapering the JAK inhibitor dosage to a group of patients continuing the full-dose. Participants will: * Either take 1. JAK inhibitor dose-tapering strategy. 2. JAK inhibitor continuous therapy strategy. * Visit the clinic once every 3 months for checkups and tests * Keep a diary of their treatment intake and symptoms
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-08
notable Trial sites expanded: 0 -> 24 locations 2026-08-08
Trial Details
NCT Number NCT06687551
Lead Sponsor University Hospital, Toulouse
Conditions Rheumatoid Arthritis (RA
Enrollment 308 participants
Start Date 2025-06-06
Primary Completion 2029-04-01 (estimated)
Study Completion 2029-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-07